Applied Biosystems has launched Assays-on-Demand products, a comprehensive set of functionally validated, ready-to-use assays specifically for genetic screening.
Applied Biosystems has launched Assays-on-Demand products, a comprehensive set of functionally validated, ready-to-use assays specifically for genetic screening.
They provide accurate, reproducible data and allow researchers to screen a greater number of targets quickly, easily and cost-effectively.
Dr Stefan Schreiber, Professor of Medicine and Gastroenterology at the University of Kiel, Germany, has been testing the assays as part of an early access programme.
"By using these assays for our systematic disease association studies, we can work effectively to identify possible mutations that may be associated with the predisposition of inflammatory bowel disease (IBD), sarcoidosis, psoriasis and peridontitis.
"In the past, we would have spent several months shifting through genomic data, developing, designing, validating and optimising our own assays.
With Applied Biosystems' approach, we can begin performing our association studies within two or three weeks of ordering these new validated and ready-to-use SNP genotyping products.
With this strategy we could generate more than 1.5 million SNP genotypes within a few months." So far, 77,000 assays for SNP genotyping and 4,400 assays for quantitative gene expression analysis have been released, and additional assays will become available in the coming months through Applied Biosystems' Knowledge Business.
All assays are optimised for use on the ABI PRISM 7900HT, 7700 and 7000 Sequence Detection Systems and can be ordered online at the Applied Biosystems store.
